Celldex Therapeutics Inc

Latest Results (14.08.2024):

Revenue

Celldex Therapeutics Inc. reported total revenue of $2.5 million for the second quarter of 2024, a significant increase compared to $0.3 million in the same quarter of 2023. For the six months ended June 30, 2024, total revenue was $2.7 million, up from $1.2 million in the comparable period of 2023.

Research and Development Expenses

Research and development (R&D) expenses for Celldex Therapeutics Inc. were $39.7 million in the second quarter of 2024, compared to $26.3 million in the second quarter of 2023. For the first half of 2024, R&D expenses totaled $71.3 million, up from $53.0 million in the same period of the previous year.

General and Administrative Expenses

General and administrative (G&A) expenses for Celldex Therapeutics Inc. were $9.1 million in the second quarter of 2024, compared to $7.2 million in the same quarter of 2023. For the six months ended June 30, 2024, G&A expenses were $18.2 million, up from $13.9 million in the comparable period of 2023.

Net Loss

Celldex Therapeutics Inc. reported a net loss of $35.8 million, or ($0.54) per share, for the second quarter of 2024. This compares to a net loss of $30.5 million, or ($0.65) per share, for the second quarter of 2023. For the six months ended June 30, 2024, the net loss was $68.7 million, or ($1.10) per share, compared to $59.9 million, or ($1.27) per share, in the same period of 2023.

Cash Position

As of June 30, 2024, Celldex Therapeutics Inc. had cash, cash equivalents, and marketable securities totaling $802.3 million. This is a substantial increase from $423.6 million as of December 31, 2023, indicating a strong financial position to support ongoing and future operations.